4 pending office actions • 4 art units • 4 examiners • 0 of 4 (0%) have an AI response strategy ready
Based on the USPTO statutory response window for each pending office action. 3 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 3 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 2 (50%) |
| §112 only | 2 (50%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| KING, DOUGLAS | 1 | 80.0% | +4.4% |
| BRISTOL, LYNN ANNE | 1 | 63.6% | +39.7% |
| KWAK, DEAN P | 1 | 58.7% | +37.4% |
| STANLEY, JANE L | 1 | 58.5% | +29.9% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18550827 | INFORMATION PROCESSING APPARATUS | KING, DOUGLAS | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18251818 | Microfluidic flow cell and system for analyzing or diagnosing biofilms and cell cultures, and the use thereof | KWAK, DEAN P | 5d |
| 18450995 | CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO | BRISTOL, LYNN ANNE | 7d |
| 17294049 | ACRYLATE COPOLYMERS FOR GALENIC APPLICATIONS | STANLEY, JANE L | 28d |
| Art Unit | Apps |
|---|---|
| 2824 | 1 |
| 1643 | 1 |
| 1798 | 1 |
| 1767 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18550827 | INFORMATION PROCESSING APPARATUS | KING, DOUGLAS | 2824 | §103 | Final Rejection | — | Pending | Sep 15, 2023 |
| 18450995 | CANCER THERAPY USING CLDN6 TARGET-DIRECTED ANTIBODIES IN VIVO | BRISTOL, LYNN ANNE | 1643 | §112Other | Non-Final OA | 7d | Pending | Aug 16, 2023 |
| 18251818 | Microfluidic flow cell and system for analyzing or diagnosing biofilms and cell cultures, and the use thereof | KWAK, DEAN P | 1798 | §103 | Final Rejection | 5d | Pending | May 04, 2023 |
| 17294049 | ACRYLATE COPOLYMERS FOR GALENIC APPLICATIONS | STANLEY, JANE L | 1767 | §112 | Non-Final OA | 28d | Pending | May 14, 2021 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial